Patents by Inventor Sandip Mehta
Sandip Mehta has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11957681Abstract: Imatinib is approved and marketed in solid oral dosage forms which may be dispersed in water or apple juice for patients having swallowing difficulty. Dispersion of Imatinib solid dosage forms in apple juice may increase palatability and patient compliance but apple juice may not be available all the time for administration. Further, dispersion of Imatinib solid oral dosage forms may not administer correct and consistent dose of medicine every time. The present invention therefore provides liquid dosage forms of Imatinib which correctly and consistently administers correct dose of drug to the patients.Type: GrantFiled: July 26, 2018Date of Patent: April 16, 2024Assignee: SHORLA PHARMA LIMITEDInventors: Sandip Mehta, Vijay Patel, Manish Umrethia, Jayanta Kumar Mandal
-
Patent number: 11931455Abstract: Disclosed herein are pharmaceutical compositions in the form of a suspension for oral delivery. Some embodiments provide a pharmaceutical composition in the form of a suspension for oral delivery comprising an active pharmaceutical ingredient; water; a suspending agent; a buffering agent; and one or more of a wetting agent and a binder/filler. In some embodiments, the active pharmaceutical ingredient is selected from quetiapine, sildenafil, tadalafil, cinacalcet, ticagrelor, mycophenolate, aprepitant, zonisamide, and primidone.Type: GrantFiled: July 31, 2023Date of Patent: March 19, 2024Assignee: LIQMEDS WORLDWIDE LIMITEDInventors: Sandip Mehta, Manish Kumar Umrethia, Jayanta Mandal
-
Patent number: 11918684Abstract: The present invention provides pharmaceutical composition of immunosuppressive agent in oral suspension dosage form. The oral suspension composition comprises of immunosuppressive agent with other pharmaceutical excipients such as vehicle, suspending agent, solvent or cosolvent, preservative, sweetener, antifoaming agent, wetting agent, buffering agent and flavouring agent. The present invention oral suspension having improved stability, palatability with high dose of active ingredient. The present invention provides oral suspension with flavor that has masked bitter taste of the drug and eliminates difficulty of administration. Further, the present invention also provides a convenient, easy process for preparation thereof.Type: GrantFiled: March 12, 2018Date of Patent: March 5, 2024Assignee: LIQMEDS WORLDWIDE LIMITEDInventors: Sandip Mehta, Manish Umrethia, Henil Patel, Jayanta Kumar Mandal
-
Publication number: 20230372238Abstract: Disclosed herein are pharmaceutical compositions in the form of a suspension for oral delivery. Some embodiments provide a pharmaceutical composition in the form of a suspension for oral delivery comprising an active pharmaceutical ingredient; water; a suspending agent; a buffering agent; and one or more of a wetting agent and a binder/filler. In some embodiments, the active pharmaceutical ingredient is selected from quetiapine, sildenafil, tadalafil, cinacalcet, ticagrelor, mycophenolate, aprepitant, zonisamide, and primidone.Type: ApplicationFiled: July 31, 2023Publication date: November 23, 2023Inventors: Sandip MEHTA, Manish Kumar UMRETHIA, Jayanta MANDAL
-
Patent number: 11738020Abstract: This disclosure relates to pharmaceutical compositions in the form of a solution for oral delivery. Particularly, the pharmaceutical compositions comprise an active pharmaceutical ingredient, a buffering agent, and water. In some embodiments, the pH of the composition is from about pH 5 to about pH 8. In some embodiments, the active pharmaceutical ingredient is selected from ramipril, solifenacin, vigabatrin, losartan potassium, warfarin, and melatonin.Type: GrantFiled: August 16, 2019Date of Patent: August 29, 2023Assignees: FTF PHARMA PRIVATE LIMITED, LM MANUFACTURING LIMITEDInventors: Sandip Mehta, Manish Kumar Umrethia, Jayanta Mandal
-
Publication number: 20230263796Abstract: This disclosure relates to pharmaceutical compositions in the form of a solution for oral delivery. Particularly, the pharmaceutical compositions comprise an active pharmaceutical ingredient, a buffering agent, and water. In some embodiments, the pH of the composition is from about pH 5 to about pH 8. In some embodiments, the active pharmaceutical ingredient is selected from ramipril, solifenacin, vigabatrin, losartan potassium, warfarin, and melatonin.Type: ApplicationFiled: May 2, 2023Publication date: August 24, 2023Inventors: Sandip MEHTA, Manish Kumar UMRETHIA, Jayanta MANDAL
-
Publication number: 20230255885Abstract: Disclosed herein are pharmaceutical compositions in the form of a suspension for oral delivery. Some embodiments provide a pharmaceutical composition in the form of a suspension for oral delivery comprising an anti-cancer active pharmaceutical ingredient; water; a suspending agent; a buffering agent; and one or more of a wetting agent and a binder/filler. In some embodiments, the anti-cancer active pharmaceutical ingredient is selected from ibrutinib, nilotinib, dasatinib, sunitinib, sorafenib, erlotinib, and capecitabine.Type: ApplicationFiled: August 16, 2019Publication date: August 17, 2023Applicants: FTF PHARMA PRIVATE LIMITED, LM MANUFACTURING LTDInventors: SANDIP MEHTA, MANISH KUMAR UMRETHIA, JAYANTA MANDAL
-
Publication number: 20230158018Abstract: Pharmaceutical compositions comprising oil as a vehicle, a suspending agent, and a surfactant are disclosed to be used in conjunction with active pharmaceutical ingredients which are water soluble or insoluble, or which are sensitive to water but insoluble in oil. Such active pharmaceutical ingredients may include temozolomide, lenalidomide, Oxaliplatin, Cisplatin, Carboplatin, 5-fluorouracil, irinotecan, topotecan, cyclophosphamide, doxorubicin, vincristine, vinblastine, Melphalan, Chlorambucil, Dacarbazine, Daunorubicin, Epirubicin, Mitoxantrone, Etoposide, Teniposide, Azacitidine, Cytarabine, Gemcitabine, vinoralbine, Pemetrexed, a derivative thereof, or a combination thereof. The pharmaceutical compositions may be administered as an oral suspension. Other embodiments are directed towards methods of using and methods of making such formulations.Type: ApplicationFiled: September 13, 2019Publication date: May 25, 2023Applicants: FTF PHARMA PRIVATE LIMITED, LM MANUFACTURING LTDInventors: VIJAY PATEL, SANDIP MEHTA, MANISH KUMAR UMRETHIA, JAYANTA MANDAL
-
Publication number: 20220160709Abstract: Imatinib is approved and marketed in solid oral dosage forms which may be dispersed in water or apple juice for patients having swallowing difficulty. Dispersion of Imatinib solid dosage forms in apple juice may increase palatability and patient compliance but apple juice may not be available all the time for administration. Further, dispersion of Imatinib solid oral dosage forms may not administer correct and consistent dose of medicine every time. The present invention therefore provides liquid dosage forms of Imatinib which correctly and consistently administers correct dose of drug to the patients.Type: ApplicationFiled: July 26, 2018Publication date: May 26, 2022Inventors: Sandip MEHTA, Vijay PATEL, Manish UMRETHIA, Jayanta Kumar MANDAL
-
Publication number: 20220023288Abstract: This disclosure relates to pharmaceutical compositions in the form of a solution for oral delivery. Particularly, the pharmaceutical compositions comprise an active pharmaceutical ingredient, a buffering agent, and water. In some embodiments, the pH of the composition is from about pH 5 to about pH 8. In some embodiments, the active pharmaceutical ingredient is selected from ramipril, solifenacin, vigabatrin, losartan potassium, warfarin, and melatonin.Type: ApplicationFiled: August 16, 2019Publication date: January 27, 2022Inventors: SANDIP MEHTA, MANISH KUMAR UMRETHIA, JAYANTA MANDAL
-
Patent number: 11147810Abstract: The present invention provides pharmaceutical composition of antineoplastic alkylating agent in oral suspension dosage form. The oral suspension composition comprises of alkylating agent with other pharmaceutical excipients such as vehicle, preservative, antioxidant, suspending agent, surfactant, sweetener and flavouring agent. The present invention is an oral suspension having improved stability and palatability. The present invention also provides oral solution with flavor that has masked bitter taste of the drug. Further, the present invention also provides a process for preparation thereof.Type: GrantFiled: March 12, 2018Date of Patent: October 19, 2021Assignee: FTF PHARMA PRIVATE LIMITEDInventors: Sandip Mehta, Manish Umrethia, Henil Patel, Jayanta Kumar Mandal
-
Publication number: 20210308044Abstract: Disclosed herein are pharmaceutical compositions in the form of a suspension for oral delivery. Some embodiments provide a pharmaceutical composition in the form of a suspension for oral delivery comprising an active pharmaceutical ingredient; water; a suspending agent; a buffering agent; and one or more of a wetting agent and a binder/filler. In some embodiments, the active pharmaceutical ingredient is selected from quetiapine, sildenafil, tadalafil, cinacalcet, ticagrelor, mycophenolate, aprepitant, zonisamide, and primidone.Type: ApplicationFiled: August 16, 2019Publication date: October 7, 2021Applicants: FTF PHARMA PRIVATE LIMITED, LM MANUFACTURING LTDInventors: SANDIP MEHTA, MANISH KUMAR UMRETHIA, JAYANTA MANDAL
-
Publication number: 20210213024Abstract: Liquid dosage forms of Aprepitant are not much explored. The present invention describes ready to use, oral liquid compositions of Aprepitant suitable for the patients having swallowing difficulties. The liquid compositions of the present invention are storage stable for prolonged time and can be used for the prevention and control of acute and delayed chemotherapy induced nausea and vomiting, and for the prevention of postoperative nausea and vomiting.Type: ApplicationFiled: February 20, 2019Publication date: July 15, 2021Applicant: FTF PHARMA PRIVATE LTDInventors: SWATI NAGAR, SANDIP MEHTA, MANISH UMRETHIA, JAYANTA KUMAR MANDAL
-
Publication number: 20210030671Abstract: Cinacalcet is approved and marketed as hydrochloride salt in a solid dosage form indicated for the treatment of secondary hyperparathyroidism resulting from chronic kidney disease and for the treatment of hypercalcemia in patients with either parathyroid carcinoma or hyperparathyroidism. Current marketed products are not allowed to be divided and to be taken whole during administration. Patients having swallowing difficulty may not show adherence to such regimen. The present invention therefore provides liquid dosage forms of Cinacalcet or pharmaceutically acceptable salt thereof.Type: ApplicationFiled: March 30, 2019Publication date: February 4, 2021Inventors: Swati NAGAR, Sandip MEHTA, Manish UMRETHIA, Jayanta Kumar MANDAL
-
Publication number: 20200246261Abstract: The present invention provides pharmaceutical composition of immunosuppressive agent in oral suspension dosage form. The oral suspension composition comprises of immunosuppressive agent with other pharmaceutical excipients such as vehicle, suspending agent, solvent or cosolvent, preservative, sweetener, antifoaming agent, wetting agent, buffering agent and flavouring agent. The present invention oral suspension having improved stability, palatability with high dose of active ingredient. The present invention provides oral suspension with flavor that has masked bitter taste of the drug and eliminates difficulty of administration. Further, the present invention also provides a convenient, easy process for preparation thereof.Type: ApplicationFiled: March 12, 2018Publication date: August 6, 2020Inventors: Sandip MEHTA, Manish UMRETHIA, Henil PATEL, Jayanta Kumar MANDAL
-
Publication number: 20200206223Abstract: Imatinib is approved and marketed in solid oral dosage forms which may be dispersed in water or apple juice for patients having swallowing difficulty. Dispersion of Imatinib solid dosage forms in apple juice may increase palatability and patient compliance but apple juice may not be available all the time for administration. Further, dispersion of Imatinib solid oral dosage forms may not administer correct and consistent dose of medicine every time. The present invention therefore provides liquid dosage forms of Imatinib which correctly and consistently administers correct dose of drug to the patients.Type: ApplicationFiled: July 26, 2018Publication date: July 2, 2020Applicant: FTF PHARMA PRIVATE LIMITEDInventors: Sandip MEHTA, Vijay PATEL, Manish UMRETHIA, Jayanta Kumar MANDAL
-
Publication number: 20200188478Abstract: Pre-mixed, ready-to-use injectable compositions possess certain advantages such as convenience and ease of use as compared to an ampule formulation, improved safety for patients due to elimination of dosage errors and solution contamination, reduction of medical waste, and ease of administration in emergency situations. Pre-mixed, ready-to-use Vancomycin injectable preparations though marketed have numbers of disadvantages which makes its handling and use difficult. The present invention therefore provides pre-mixed, ready-to-use injectable formulations of Vancomycin which eliminates disadvantages and difficulties of the marketed product and at the same time maintains desired stability for prolonged time.Type: ApplicationFiled: December 12, 2019Publication date: June 18, 2020Applicant: FTF PHARMA PRIVATE LIMITEDInventors: Dhaval CHANDARANA, Sandip MEHTA, Manish UMRETHIA, Rutul PATEL, Hardik PRAJAPATI, Malay PATEL, Jayanta Kumar MANDAL
-
Publication number: 20200069678Abstract: The present invention provides pharmaceutical composition of antineoplastic alkylating agent in oral suspension dosage form. The oral suspension composition comprises of alkylating agent with other pharmaceutical excipients such as vehicle, preservative, antioxidant, suspending agent, surfactant, sweetener and flavouring agent. The present invention is an oral suspension having improved stability and palatability. The present invention also provides oral solution with flavor that has masked bitter taste of the drug. Further, the present invention also provides a process for preparation thereof.Type: ApplicationFiled: March 12, 2018Publication date: March 5, 2020Inventors: Sandip MEHTA, Manish UMRETHIA, Henil PATEL, Jayanta Kumar MANDAL
-
Publication number: 20200046664Abstract: The present invention discloses a processes for the preparation of a stable liquid pharmaceutical composition comprising levothyroxine or pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients wherein the liquid composition of the present invention is used for oral administration. The present invention also discloses stable liquid compositions comprising levothyroxine or pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients prepared according to the processes of the present invention.Type: ApplicationFiled: October 7, 2017Publication date: February 13, 2020Inventors: Vijay PATEL, Sandip MEHTA, Manoj KALAVADIYA, Manish UMRETHIA, Jayanta Kumar MANDAL
-
Publication number: 20200022910Abstract: The present invention provides pharmaceutical composition of muscarinic antagonist in oral solution dosage form. The oral solution composition comprises of muscarinic antagonist with other pharmaceutical excipients such as vehicle, preservative, buffering agent, sweetener and flavouring agent. The present invention is an oral solution of muscarinic antagonist that is free from allergic preservatives and having improved stability without risk of over dosage of the drug. The present invention also provides oral solution with flavor that has masked bitter taste of muscarinic antagonist. Further, the present invention also provides a process for preparation thereof.Type: ApplicationFiled: February 23, 2018Publication date: January 23, 2020Inventors: Sandip MEHTA, Manish UMRETHIA, Jayanta Kumar MANDAL